Tesofensine
Overview[edit]
Tesofensine is a pharmacological compound that has been investigated for its potential use in the treatment of obesity. It functions primarily as a monoamine reuptake inhibitor, affecting the levels of neurotransmitters such as dopamine, norepinephrine, and serotonin in the brain.
Mechanism of Action[edit]
Tesofensine works by inhibiting the reuptake of key neurotransmitters, which leads to increased levels of these chemicals in the synaptic cleft. This action is believed to enhance satiety and reduce appetite, contributing to weight loss in individuals with obesity. The compound's effect on dopamine and norepinephrine is particularly significant, as these neurotransmitters are involved in the regulation of mood and energy expenditure.
Clinical Development[edit]
Tesofensine was initially developed for the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. However, during clinical trials, it was observed that patients experienced significant weight loss, leading to a shift in focus towards its potential as an anti-obesity medication.
Clinical Trials[edit]
Several clinical trials have been conducted to evaluate the efficacy and safety of tesofensine in promoting weight loss. These studies have demonstrated that tesofensine can lead to significant reductions in body weight compared to placebo. However, the trials also highlighted potential side effects, including increased heart rate and blood pressure, which necessitate careful consideration in its use.
Side Effects[edit]
The use of tesofensine has been associated with several side effects, primarily related to its action on the central nervous system. Common side effects include insomnia, dry mouth, and constipation. More serious cardiovascular effects, such as tachycardia and hypertension, have also been reported, which may limit its use in certain populations.
Future Directions[edit]
Research into tesofensine continues, with ongoing studies aimed at optimizing its therapeutic profile and minimizing adverse effects. The development of combination therapies and the identification of specific patient populations that may benefit most from tesofensine are areas of active investigation.
Related Pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian